{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2006-N-0040\" and posted_year = 2015 sorted by posted_date descending", "rows": [["FDA-2006-N-0040-0009", "FDA", "FDA-2006-N-0040", "Requirements for Blood and Blood Components Intended for Transfusion\nor for Further Manufacturing Use", "Rule", "Final Rule", "2015-05-22T04:00:00Z", 2015, 5, "2015-05-22T04:00:00Z", null, "2024-11-07T23:21:58Z", "2015-12228", 1, 0, "0900006481af12e2"], ["FDA-2006-N-0040-0073", "FDA", "FDA-2006-N-0040", "Reference 63 Donor Deferral Due to Red Blood Cell Loss During Collection by Automated Plasmapheresis re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:24:31Z", null, 0, 0, "0900006481aef991"], ["FDA-2006-N-0040-0101", "FDA", "FDA-2006-N-0040", "Reference 77-14 Relationship between Bacterial Load, Species Virulence, and Transfusion Reaction with Transfusion re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:33:00Z", null, 0, 0, "0900006481aef9ad"], ["FDA-2006-N-0040-0054", "FDA", "FDA-2006-N-0040", "Reference 44 BPAC June 2010 re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:22:02Z", null, 0, 0, "0900006481aef772"], ["FDA-2006-N-0040-0090", "FDA", "FDA-2006-N-0040", "Reference 77-3 AABB Bulletin 08-03 \u2013 West Nile Virus \u2013 Revised Recommendations for Triggering Individual Donation Nucleic Acid Testing  re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:31:29Z", null, 0, 0, "0900006481aef9a2"], ["FDA-2006-N-0040-0010", "FDA", "FDA-2006-N-0040", "Reference List re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T18:53:43Z", null, 0, 0, "0900006481aef5f7"], ["FDA-2006-N-0040-0016", "FDA", "FDA-2006-N-0040", "Reference 6 Implementation of Acceptable Full-Length Donor History Questionnaire re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:09:02Z", null, 0, 0, "0900006481aef5fd"], ["FDA-2006-N-0040-0028", "FDA", "FDA-2006-N-0040", "Reference 18 How Do I Investigate Septic Transfusion Reactions and Blood Donors with Culture-Positive Platelet Donations re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:18:12Z", null, 0, 0, "0900006481aef758"], ["FDA-2006-N-0040-0055", "FDA", "FDA-2006-N-0040", "Reference 45 ACBSA Meeting Minutes December 2008 re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:22:12Z", null, 0, 0, "0900006481aef773"], ["FDA-2006-N-0040-0015", "FDA", "FDA-2006-N-0040", "Reference 5 Transfusion-transmitted Emerging Infectious Diseases  30 years of Challenges and Progress re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:08:42Z", null, 0, 0, "0900006481aef5fc"], ["FDA-2006-N-0040-0069", "FDA", "FDA-2006-N-0040", "Reference 59 Evaluating the Role of Blood Collection Centers in Public Health  A Status Report re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:24:01Z", null, 0, 0, "0900006481aef98d"], ["FDA-2006-N-0040-0052", "FDA", "FDA-2006-N-0040", "Reference 42 Faint and Prefaint Reactions in Whole-Blood Donors  An Analysis of Predonation Measurements and Their Predictive Value re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:21:40Z", null, 0, 0, "0900006481aef770"], ["FDA-2006-N-0040-0087", "FDA", "FDA-2006-N-0040", "Reference 77 Regulatory Impact Analysis re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:26:38Z", null, 0, 0, "0900006481aef99f"], ["FDA-2006-N-0040-0019", "FDA", "FDA-2006-N-0040", "Reference 9 Transmission of HIV Possibly Associated with Exposure of Mucous Membrane to Contaminated Blood re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:10:04Z", null, 0, 0, "0900006481aef74f"], ["FDA-2006-N-0040-0049", "FDA", "FDA-2006-N-0040", "Reference 39 Recommendations for Assesment of Donor Suitability and Blood and Blood Product Safety in Cases of Possible Exposure to Anthrax re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:21:19Z", null, 0, 0, "0900006481aef76d"], ["FDA-2006-N-0040-0053", "FDA", "FDA-2006-N-0040", "Reference 43 BPAC Sept 10 2008 Agenda re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:21:53Z", null, 0, 0, "0900006481aef771"], ["FDA-2006-N-0040-0012", "FDA", "FDA-2006-N-0040", "Reference 2 United States House of Representatives, Committee on Government Reform and Oversight, Subcommittee on Human Resources and Intergovernmental Relations re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T18:55:23Z", null, 0, 0, "0900006481aef5f9"], ["FDA-2006-N-0040-0014", "FDA", "FDA-2006-N-0040", "Reference 4 Emerging Infectious Disease Agents and Their Potential Threat to Transfusion Safety re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T18:55:43Z", null, 0, 0, "0900006481aef5fb"], ["FDA-2006-N-0040-0036", "FDA", "FDA-2006-N-0040", "Reference 26 BPAC Sept 2000 re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:19:13Z", null, 0, 0, "0900006481aef760"], ["FDA-2006-N-0040-0059", "FDA", "FDA-2006-N-0040", "Reference 49 The difference between fingerstick and venous hemoglobin re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:22:40Z", null, 0, 0, "0900006481aef778"], ["FDA-2006-N-0040-0081", "FDA", "FDA-2006-N-0040", "Reference 71 Study of Iron Stores in Regular Plateletphereis Donors re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:25:49Z", null, 0, 0, "0900006481aef999"], ["FDA-2006-N-0040-0092", "FDA", "FDA-2006-N-0040", "Reference 77-5 Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:31:43Z", null, 0, 0, "0900006481aef9a4"], ["FDA-2006-N-0040-0038", "FDA", "FDA-2006-N-0040", "Reference  28 Guidance for Industry Donor Screening re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:19:28Z", null, 0, 0, "0900006481aef762"], ["FDA-2006-N-0040-0050", "FDA", "FDA-2006-N-0040", "Reference 40 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:21:27Z", null, 0, 0, "0900006481aef76e"], ["FDA-2006-N-0040-0060", "FDA", "FDA-2006-N-0040", "Reference 50 Iron Deficiency in Blood Donors the REDS II Donor Iron Status Evaluation (RISE II) Study re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:22:47Z", null, 0, 0, "0900006481aef77a"], ["FDA-2006-N-0040-0080", "FDA", "FDA-2006-N-0040", "Reference 70  Impairment of short term memory loss Associated with Low Iron Stores in a Volunteer Multidose Plateletpheresis Donor re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:25:25Z", null, 0, 0, "0900006481aef998"], ["FDA-2006-N-0040-0043", "FDA", "FDA-2006-N-0040", "Reference 33 Community Blood Donors\u2019 Knowledge of Anemia and Design of a Literacy-Appropriate Educational Intervention re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:20:27Z", null, 0, 0, "0900006481aef767"], ["FDA-2006-N-0040-0063", "FDA", "FDA-2006-N-0040", "Reference 53 Recommendations for collecting Red Blood re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:23:09Z", null, 0, 0, "0900006481aef77d"], ["FDA-2006-N-0040-0076", "FDA", "FDA-2006-N-0040", "Reference 66 Plasma proteins and lymphocyte phenoyptes in long term plasma donors re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:24:53Z", null, 0, 0, "0900006481aef994"], ["FDA-2006-N-0040-0085", "FDA", "FDA-2006-N-0040", "Reference 75 Safety Reporting Requirements for Human Drug and Biological Products Proposed Rule re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:26:24Z", null, 0, 0, "0900006481aef99d"], ["FDA-2006-N-0040-0058", "FDA", "FDA-2006-N-0040", "Reference 48 Examination of Blood Cells Willliams Hematology re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:22:33Z", null, 0, 0, "0900006481aef777"], ["FDA-2006-N-0040-0021", "FDA", "FDA-2006-N-0040", "Reference 11 Revised Preventive Measures to Reduce Risk of Tranmsission of CJD and vCJD re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:10:50Z", null, 0, 0, "0900006481aef751"], ["FDA-2006-N-0040-0027", "FDA", "FDA-2006-N-0040", "Reference 17 Further Guidance on Methods to Detect Bacterial Contamination of Platelet Components re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:18:06Z", null, 0, 0, "0900006481aef757"], ["FDA-2006-N-0040-0065", "FDA", "FDA-2006-N-0040", "Reference 55 Use of Blood Therapeutically Drawn From Hemochromatosis Patients re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:23:28Z", null, 0, 0, "0900006481aef77f"], ["FDA-2006-N-0040-0022", "FDA", "FDA-2006-N-0040", "Reference 12 Screening of Single-Donor Apheresis Platelets for Bacterial Contamination  the PASSPORT Study Results re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:11:12Z", null, 0, 0, "0900006481aef752"], ["FDA-2006-N-0040-0061", "FDA", "FDA-2006-N-0040", "Reference 51 Vital Signs Anthropometric Data and Pain Introduction re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:22:54Z", null, 0, 0, "0900006481aef77b"], ["FDA-2006-N-0040-0098", "FDA", "FDA-2006-N-0040", "Reference 77-11 Regulatory Impact Analysis Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:32:34Z", null, 0, 0, "0900006481aef9aa"], ["FDA-2006-N-0040-0032", "FDA", "FDA-2006-N-0040", "Reference 22 A Computerized National Blood Donor Deferral Register,\u201d The Journal of the American Medical Association re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:18:42Z", null, 0, 0, "0900006481aef75c"], ["FDA-2006-N-0040-0024", "FDA", "FDA-2006-N-0040", "Reference 14 Relationship Between Bacterial Load, Species Virulence, and Transfusion Reaction with Transfusion of Bacterially Contaminated Platelets,\u201d Clinical Infectious Disease re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:17:45Z", null, 0, 0, "0900006481aef754"], ["FDA-2006-N-0040-0057", "FDA", "FDA-2006-N-0040", "Reference 47 Effect of Reversible Androgen Deprivation on Hemoglobin and Serum Immunoreactive Erythropoietin in Men re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:22:25Z", null, 0, 0, "0900006481aef775"], ["FDA-2006-N-0040-0031", "FDA", "FDA-2006-N-0040", "Reference 21 An Evaluation of the Need for Shared Blood Donor Deferral Registries re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:18:35Z", null, 0, 0, "0900006481aef75b"], ["FDA-2006-N-0040-0035", "FDA", "FDA-2006-N-0040", "Reference 25 April 2009 BPAC Transcripts UCM155628 pdf re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:19:06Z", null, 0, 0, "0900006481aef75f"], ["FDA-2006-N-0040-0084", "FDA", "FDA-2006-N-0040", "Reference 74 QSEAL Plasma Protein Therapeutics Association (PPTA) re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:26:17Z", null, 0, 0, "0900006481aef99c"], ["FDA-2006-N-0040-0088", "FDA", "FDA-2006-N-0040", "Reference 77-1 Occupational Employment Statistics re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:26:45Z", null, 0, 0, "0900006481aef9a0"], ["FDA-2006-N-0040-0072", "FDA", "FDA-2006-N-0040", "Reference 62 Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:24:23Z", null, 0, 0, "0900006481aef990"], ["FDA-2006-N-0040-0062", "FDA", "FDA-2006-N-0040", "Reference 52 BPAC April 2011 re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:23:02Z", null, 0, 0, "0900006481aef77c"], ["FDA-2006-N-0040-0067", "FDA", "FDA-2006-N-0040", "Reference 57 Blood from Patients with Hereditary Hemochromatosisa Wasted Resource re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:23:44Z", null, 0, 0, "0900006481aef98b"], ["FDA-2006-N-0040-0078", "FDA", "FDA-2006-N-0040", "Reference 68 A Frequent Plateletpheresis Does Not Clinically Significantly Decrease Platelet Counts in Donors re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:25:09Z", null, 0, 0, "0900006481aef996"], ["FDA-2006-N-0040-0082", "FDA", "FDA-2006-N-0040", "Reference 72 Influence of multicomonent aheresis on donors re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:25:55Z", null, 0, 0, "0900006481aef99a"], ["FDA-2006-N-0040-0071", "FDA", "FDA-2006-N-0040", "Reference 61 Multiple Myeloma re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:24:16Z", null, 0, 0, "0900006481aef98f"], ["FDA-2006-N-0040-0039", "FDA", "FDA-2006-N-0040", "Reference  29 Guidance for Industry Requalification Method re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:19:36Z", null, 0, 0, "0900006481aef763"], ["FDA-2006-N-0040-0100", "FDA", "FDA-2006-N-0040", "Reference 77-13 Public Conference  Secondary Bacterial Screening of Platelet Components re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:32:49Z", null, 0, 0, "0900006481aef9ac"], ["FDA-2006-N-0040-0042", "FDA", "FDA-2006-N-0040", "Reference 32 Donor fatigue. The Red Cross Has Banned Chronic Fatigue Syndrome Sufferers from Giving Blood. But Does a Virus Really Cause the Disease re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:20:02Z", null, 0, 0, "0900006481aef766"], ["FDA-2006-N-0040-0070", "FDA", "FDA-2006-N-0040", "Reference 60 Specific Proteins Henry's Clinical Diagnosis re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:24:09Z", null, 0, 0, "0900006481aef98e"], ["FDA-2006-N-0040-0030", "FDA", "FDA-2006-N-0040", "Reference 20 Public Conference July 17 2002 \u2013 Secondary Bacterial Screening of Platelet Components, 7_ re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:18:27Z", null, 0, 0, "0900006481aef75a"], ["FDA-2006-N-0040-0040", "FDA", "FDA-2006-N-0040", "Reference 30 Recommendations to Decrease the Risk of Transmitting Acquired Immune Deficiency Syndrome (AIDS) from Blood Donors re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:19:47Z", null, 0, 0, "0900006481aef764"], ["FDA-2006-N-0040-0075", "FDA", "FDA-2006-N-0040", "Reference 65 Specific Protein Content of Pools of Plasma for Fractionation from Different Sources  Impact of Frequency of Donations re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:24:46Z", null, 0, 0, "0900006481aef993"], ["FDA-2006-N-0040-0099", "FDA", "FDA-2006-N-0040", "Reference 77-12 U.S. Centers for Disease Control and Prevention, Hepatitis C Fact Sheet re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:32:41Z", null, 0, 0, "0900006481aef9ab"], ["FDA-2006-N-0040-0025", "FDA", "FDA-2006-N-0040", "Reference 15 Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for Fiscal Year 2012 re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:17:51Z", null, 0, 0, "0900006481aef755"], ["FDA-2006-N-0040-0074", "FDA", "FDA-2006-N-0040", "Reference 64 Collection of Platelets by Automated Methods re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:24:39Z", null, 0, 0, "0900006481aef992"], ["FDA-2006-N-0040-0086", "FDA", "FDA-2006-N-0040", "Reference 76 Exceptions and Alternative Procedures Approved Under 21 CFR 640 re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:26:31Z", null, 0, 0, "0900006481aef99e"], ["FDA-2006-N-0040-0066", "FDA", "FDA-2006-N-0040", "Reference 56 Blood Safety Summary April 1999 re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:23:37Z", null, 0, 0, "0900006481aef780"], ["FDA-2006-N-0040-0089", "FDA", "FDA-2006-N-0040", "Reference 77-2 AABB Bulletin 06-08 Information Concerning Implementation of a Licensed Test for Antibodies to Trypanosoma cruzi re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:26:51Z", null, 0, 0, "0900006481aef9a1"], ["FDA-2006-N-0040-0045", "FDA", "FDA-2006-N-0040", "Reference  35 Guidance for Industry Assessing Donor Suitability West Nile June 2005 re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:20:50Z", null, 0, 0, "0900006481aef769"], ["FDA-2006-N-0040-0026", "FDA", "FDA-2006-N-0040", "Reference 16 Commission on Laboratory Accreditation Laboratory Accreditation Program re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:18:00Z", null, 0, 0, "0900006481aef756"], ["FDA-2006-N-0040-0083", "FDA", "FDA-2006-N-0040", "Reference 73 Blood Plasma Safety-Plasma Product Risks Are Low if Good Manufacturing Practices are Followed re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:26:02Z", null, 0, 0, "0900006481aef99b"], ["FDA-2006-N-0040-0091", "FDA", "FDA-2006-N-0040", "Reference 77-4 Use of Serological Testss to Reduce the Risk of Transmission of Trypanosoma cruzi re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:31:36Z", null, 0, 0, "0900006481aef9a3"], ["FDA-2006-N-0040-0011", "FDA", "FDA-2006-N-0040", "Reference 1 Department of Health and Human Services, Blood Action Plan, FDACBER, July 1997 re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T18:55:08Z", null, 0, 0, "0900006481aef5f8"], ["FDA-2006-N-0040-0013", "FDA", "FDA-2006-N-0040", "Reference 3 U. S. General Accounting Office, \u201cBlood Supply FDA Oversight and Remaining Issues of Safety re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T18:55:33Z", null, 0, 0, "0900006481aef5fa"], ["FDA-2006-N-0040-0029", "FDA", "FDA-2006-N-0040", "Reference  19 Gold JS Bayor S Salem RR Association of Streptococcus re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:18:19Z", null, 0, 0, "0900006481aef759"], ["FDA-2006-N-0040-0020", "FDA", "FDA-2006-N-0040", "Reference 10 Memorandum Revised Recommendations for the Prevention of Human Immunodeficiency Virus (HIV) Transmission by Blood and Blood Products (April 23, 1992) re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:10:30Z", null, 0, 0, "0900006481aef750"], ["FDA-2006-N-0040-0023", "FDA", "FDA-2006-N-0040", "Reference 13 ph and Glucose Testing of Single Donor Apheresis Platelets Should be Discontinued In Favor of a More Sensitive Detection Method re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:17:29Z", null, 0, 0, "0900006481aef753"], ["FDA-2006-N-0040-0068", "FDA", "FDA-2006-N-0040", "Reference 58 Evaluating the role of blood collection in public health re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:23:52Z", null, 0, 0, "0900006481aef98c"], ["FDA-2006-N-0040-0056", "FDA", "FDA-2006-N-0040", "Reference 46 Public Workshops Hemoglobin Standards and Maintaining Adequate Iron Stores in Blood Donors re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:22:19Z", null, 0, 0, "0900006481aef774"], ["FDA-2006-N-0040-0095", "FDA", "FDA-2006-N-0040", "Reference 77-8 AABB Bulletin 10-05 Suggested Options For Transfusion Services re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:32:09Z", null, 0, 0, "0900006481aef9a7"], ["FDA-2006-N-0040-0097", "FDA", "FDA-2006-N-0040", "Reference 77-10 U.S. Centers for Disease Control and Prevention, Hepatitis B Fact Sheet re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:32:26Z", null, 0, 0, "0900006481aef9a9"], ["FDA-2006-N-0040-0018", "FDA", "FDA-2006-N-0040", "Reference 8 Impementation of an Acceptable Abbreviated Donor Hisotry Questionnaire and Accompanying Materials for Use in Screening Donors of Blood and Blood Components re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:09:44Z", null, 0, 0, "0900006481aef74e"], ["FDA-2006-N-0040-0034", "FDA", "FDA-2006-N-0040", "Reference  24 Guidance For Industry Use of Serological Tests to Reduce the Risk of Transmission of T  Cruzi re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:18:59Z", null, 0, 0, "0900006481aef75e"], ["FDA-2006-N-0040-0046", "FDA", "FDA-2006-N-0040", "Reference  36 Guidance for Industry Revised Recommendations for the Asssessment of Donor Suitability SARS re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:20:58Z", null, 0, 0, "0900006481aef76a"], ["FDA-2006-N-0040-0094", "FDA", "FDA-2006-N-0040", "Reference 77-7 The 2011 National Blood Collection and Utilization Survey and Report re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:31:59Z", null, 0, 0, "0900006481aef9a6"], ["FDA-2006-N-0040-0051", "FDA", "FDA-2006-N-0040", "Reference 41 A Case-Controlled Multicenter Study of Vasovagal Reactions in Blood Donors Influence of Sex, Age, Donation Status, Weight, Blood Pressure and Pulse re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:21:34Z", null, 0, 0, "0900006481aef76f"], ["FDA-2006-N-0040-0096", "FDA", "FDA-2006-N-0040", "Reference 77-9 The hazards of blood transfusion in historical perspective re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:32:16Z", null, 0, 0, "0900006481aef9a8"], ["FDA-2006-N-0040-0044", "FDA", "FDA-2006-N-0040", "Reference  34 Guidance for Industry Recommendations for Blood Establishments Training of Back Up Personnel re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:20:42Z", null, 0, 0, "0900006481aef768"], ["FDA-2006-N-0040-0093", "FDA", "FDA-2006-N-0040", "Reference 77-6 Public Conference July 17 2012 Secondary Bacterial Screening of Platelet Components re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:31:51Z", null, 0, 0, "0900006481aef9a5"], ["FDA-2006-N-0040-0037", "FDA", "FDA-2006-N-0040", "Reference 27 Antiphospholipid Syndrome  Laboratory Testing and Diagnostic Strategies re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:19:20Z", null, 0, 0, "0900006481aef761"], ["FDA-2006-N-0040-0079", "FDA", "FDA-2006-N-0040", "Reference 69 Sustained Decreases in Platelet Count Associated with Multiple, Regular Plateletpheresis Donations re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:25:16Z", null, 0, 0, "0900006481aef997"], ["FDA-2006-N-0040-0017", "FDA", "FDA-2006-N-0040", "Reference 7 Impementation of an Acceptable Abbreviated Donor Hisotry Questionnaire and Accompanying Materials for Use in Screening Donors of Source Plasma re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:09:23Z", null, 0, 0, "0900006481aef5fe"], ["FDA-2006-N-0040-0041", "FDA", "FDA-2006-N-0040", "Reference 31 Deferral for Risk of Leishmaniasis Exposure re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:19:55Z", null, 0, 0, "0900006481aef765"], ["FDA-2006-N-0040-0077", "FDA", "FDA-2006-N-0040", "Reference 67 Revised Recommendations for Testing Whole Blood Blood Components Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV) re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:25:01Z", null, 0, 0, "0900006481aef995"], ["FDA-2006-N-0040-0047", "FDA", "FDA-2006-N-0040", "Reference  37 Draft Guidance for Industry Precautionary Measures to Reduce   Zoonosis re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:21:05Z", null, 0, 0, "0900006481aef76b"], ["FDA-2006-N-0040-0033", "FDA", "FDA-2006-N-0040", "Reference 23 National Donor Deferral Registry (NDDR) re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:18:49Z", null, 0, 0, "0900006481aef75d"], ["FDA-2006-N-0040-0048", "FDA", "FDA-2006-N-0040", "Reference  38 Memorandum to Blood Establishments Deferral of BLood and Plasma Donors based on Medications re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:21:13Z", null, 0, 0, "0900006481aef76c"], ["FDA-2006-N-0040-0064", "FDA", "FDA-2006-N-0040", "Reference 54 Variances for Blood Collection from Indviduals with Hereditary Hemochromatosis re Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use", "Supporting & Related Material", "Background Material", "2015-05-22T04:00:00Z", 2015, 5, null, null, "2015-05-22T19:23:20Z", null, 0, 0, "0900006481aef77e"]], "truncated": false, "filtered_table_rows_count": 93, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 and \"posted_year\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA-2006-N-0040", "p1": "2015"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2006-N-0040&posted_year=2015", "results": [{"value": "FDA", "label": "FDA", "count": 93, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2006-N-0040&posted_year=2015&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2006-N-0040&posted_year=2015", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 92, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2006-N-0040&posted_year=2015&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Rule", "label": "Rule", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2006-N-0040&posted_year=2015&document_type=Rule", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2006-N-0040&posted_year=2015", "results": [{"value": 2015, "label": 2015, "count": 93, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2006-N-0040", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2006-N-0040&posted_year=2015&_facet=subtype"}, {"name": "open_for_comment", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2006-N-0040&posted_year=2015&_facet=open_for_comment"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2006-N-0040&posted_year=2015&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2006-N-0040&posted_year=2015&_facet_date=comment_start_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2006-N-0040&posted_year=2015&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 633.9804629678838, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}